GH1 and neoplasm: In relation to the pathological subtypes of GH&PRL-PAs according to the WHO 2022 classification (n = 67), most of them were classified as mammosomatotroph (n = 50), followed by somatotroph (n = 8), lactotroph (n = 2) and mature or immature plurihormonal PIT1-lineage tumor (n = 7).